Postmenopausal Hormone Therapy is Associated with in Situ Breast Cancer Risk

  • Ni, Xiao-Jian (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) ;
  • Xia, Tian-Song (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) ;
  • Zhao, Ying-Chun (Department of Breast Surgery, the Second People's Hospital affiliated with Wannan Medical College) ;
  • Ma, Jing-Jing (State Key Laboratory of Reproductive Medicine, Department of Breast Surgery, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University) ;
  • Zhao, Jie (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) ;
  • Liu, Xiao-An (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) ;
  • Ding, Qiang (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) ;
  • Zha, Xiao-Ming (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) ;
  • Wang, Shui (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University)
  • Published : 2012.08.31


Background: The relationship between postmenopausal hormone therapy (HT) and invasive breast cancer has been extensively investigated, but that with breast carcinoma in situ (BCIS) has received relatively little attention. The aim of our present study was to review and summarize the evidence provided by longitudinal studies on the association between postmenopausal HT use and BCIS risk. Methods: A comprehensive literature search for articles published up to May 2012 was performed. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Relative risk (RR) or odds ratio (OR) values were calculated using 14 reports (8 case-control studies and 6 cohort studies), published between 1986 and 2012. Results: There was evidence of an association between ever postmenopausal estrogen use and BCIS based on a random-effects model (RR = 1.25, 95% confidence interval (CI) = 1.01, 1.55). However, we found no strong evidence of an association between ever postmenopausal estrogen combined with progesterone use and BCIS using a randomeffects model (RR = 1.55, 95% CI = 0.95, 2.51). Furthermore, our analysis showed a strong association between "> 5 years duration" of estrogen or estrogen combined with progesterone use and BCIS. Furthermore, current use of any HT is associated with increased risk of BCIS in cohort studies. Additional well-designed large studies are now required to validate this association in different populations.


  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
  2. Biglia N, Sgro L, Defabiani E, et al (2005). The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol, 31, 467-72.
  3. Bonovas S, Filioussi K, Sitaras NM (2005). Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol, 60, 194-203.
  4. Breen N, Kessler L (1994). Changes in the use of screening mammography: evidence from the 1987 and 1990 National Health Interview Surveys. Am J Public Health, 84, 62-7.
  5. Brinton LA, Hoover R, Fraumeni JF Jr. (1986). Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer, 54, 825-32.
  6. Calvocoressi L, Stowe MH, Carter D, et al (2012). Postmenopausal hormone therapy and ductal carcinoma in situ: a populationbased case-control study. Cancer Epidemiol, 36, 161-8.
  7. Chen WY, Hankinson SE, Schnitt SJ, et al (2004). Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer, 101, 1490-500.
  8. Chlebowski RT, Hendrix SL, Langer RD, et al (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA, 289, 3243-53.
  9. Claus EB, Stowe M, Carter D (2001). Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst, 93, 1811-7.
  10. Collins JA, Blake JM, Crosignani PG (2005). Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update, 11, 545-60.
  11. Daling JR, Malone KE, Doody DR, et al (2002). Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer, 95, 2455-64.
  12. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  13. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  14. Ernster VL, Ballard-Barbash R, Barlow WE, et al (2002). Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst, 94, 1546-54.
  15. Gapstur SM, Morrow M, Sellers TA (1999). Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA, 281, 2091-7.
  16. Greendale GA, Reboussin BA, Sie A, et al (1999). Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med, 130, 262-9.
  17. Gupta SK, Douglas-Jones AG, Fenn N, et al (1997). The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer, 80, 1740-5.<1740::AID-CNCR7>3.0.CO;2-I
  18. Henrich JB, Kornguth PJ, Viscoli CM, et al (1998). Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol, 51, 1277-83.
  19. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  20. Kabat GC, Kim MY, Woods NF, et al (2011). Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control, 22, 1415-24.
  21. Kerlikowske K (2010). Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr, 139-41.
  22. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al (2003). Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol, 21, 4314-21.
  23. Kopans DB, Rafferty E, Georgian-Smith D, et al (2003). A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. Cancer, 97, 2951-9.
  24. Lari SA, Kuerer HM (2011). Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer, 2, 232-61.
  25. Laya MB, Larson EB, Taplin SH, et al (1996). Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst, 88, 643-9.
  26. Longnecker MP, Bernstein L, Paganini-Hill A, et al (1996). Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev, 5, 961-5.
  27. Lyytinen H, Pukkala E, Ylikorkala O (2006). Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol, 108, 1354-60.
  28. Lyytinen H, Pukkala E, Ylikorkala O (2009). Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol, 113, 65-73.
  29. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  30. Mariuzzi GM, Mariuzzi L, Mombello A, et al (1994). Quantitative study of ductal breast cancer progression. Morphometric evaluation of phenotypical changes occurring in benign and preinvasive epithelial lesions. Pathol Res Pract, 190, 1056-65.
  31. Miller FR, Soule HD, Tait L, et al (1993). Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst, 85, 1725-32.
  32. Page DL, Dupont WD, Rogers LW, et al (1995). Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer, 76, 1197-200.<1197::AID-CNCR2820760715>3.0.CO;2-0
  33. Persson I, Thurfjell E, Holmberg L (1997). Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol, 15, 3201-7.
  34. Phillips LS, Millikan RC, Schroeder JC, et al (2009). Reproductive and hormonal risk factors for ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev, 18, 1507-14.
  35. Phipps AI, Li CI, Kerlikowske K, et al (2010). Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol Biomarkers Prev, 19, 1643-54.
  36. Quinn CM, Ostrowski JL, Parkin GJ, et al (1997). Ductal carcinoma in situ of the breast: the clinical significance of histological classification. Histopathology, 30, 113-9.
  37. Reeves GK, Beral V, Green J, et al (2006). Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol, 7, 910-8.
  38. Reeves GK, Pirie K, Green J, et al (2012). Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer, 131, 930-7.
  39. Reinier KS, Vacek PM, Geller BM (2007). Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Breast Cancer Res Treat, 103, 343-8.
  40. Renshaw AA (2002). Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ. Arch Pathol Lab Med, 126, 39-41.
  41. Ross RK, Paganini-Hill A, Wan PC, et al (2000). Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst, 92, 328-32.
  42. Schairer C, Byrne C, Keyl PM, et al (1994). Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control, 5, 491-500.
  43. Seeley T (1994). Do women taking hormone replacement therapy have a higher uptake of screening mammograms? Maturitas, 19, 93-6.
  44. Stanford JL, Weiss NS, Voigt LF, et al (1995). Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA, 274, 137-42.
  45. Stoll BA (2000). Biological mechanisms in breast cancer invasiveness: relevance to preventive interventions. Eur J Cancer Prev, 9, 73-9.
  46. Strah KM, Love SM (1992). The in situ carcinomas of the breast. J Am Med Womens Assoc, 47, 165-8.
  47. Trentham-Dietz A, Newcomb PA, Storer BE, et al (2000). Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev, 9, 697-703.
  48. Warnberg F, Yuen J, Holmberg L (2000). Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet, 355, 724-5.
  49. Wysowski DK, Golden L, Burke L (1995). Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol, 85, 6-10.

Cited by

  1. Validation of Electrical Impedance Tomography Qualitative and Quantitative Values and Comparison of the Numeric Pain Distress Score against Mammography vol.15, pp.14, 2014,
  2. Risk of Breast Cancer and Total Malignancies in Rheumatoid Arthritis Patients Undergoing TNF-α Antagonist Therapy: a Meta-analysis of Randomized Control Trials vol.15, pp.8, 2014,
  3. Egg consumption and breast cancer risk: a meta-analysis vol.21, pp.3, 2014,
  4. Hormone und das Risiko für Brustkrebs und gynäkologische Malignome vol.50, pp.1, 2017,